Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 … – StreetInsider

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small …

Do you trust this headline?

Based on recent headline ratings, 100% of this readership currently trusts the local media, which has an average score of 84% regionally and is currently trending positivepositive.


Media Trust Score100%